Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of AZD2373 in Healthy Men of African Ancestry
NCT04269031Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2020
- Primary completion
- Aug 2021
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of opemalirsen in APOL1-mediated kidney disease (AMKD) (6 cohorts), sponsored by AstraZeneca. Primary endpoint: Number of subjects with adverse events and/or abnormal findings. Started Feb 2020; status: completed.
02
Drugs
opemalirsen
03
Conditions
APOL1-mediated kidney disease (AMKD)
Beyond the preview
Go deeper on NCT04269031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04269031.